Live Crown Castle Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about

GYRE THERAPEUTICS, INC.

GYRE

Latest SEC Filings from GYRE THERAPEUTICS, INC.

  1. 1
    1

    Gyre Therapeutics Reports $14.3 Million Net Loss in Q2 2026, Revenue Declines 2%

    via official filing (AI summary) 3 months ago 0 comments
  2. 2
    1

    Gyre Therapeutics Reports $9.9 Million Net Loss in Q1 2026 Amid Increased Revenue and Operating Expenses

    via official filing (AI summary) 6 months ago 0 comments
  3. 3
    1

    Gyre Therapeutics Reports $116.6M Revenue and $9.9M Net Income for Fiscal Year 2025

    via official filing (AI summary) 8 months ago 0 comments
  4. 4
    1

    Gyre Therapeutics Reports 20% Revenue Growth to $30.6 Million in Q3 2025

    via official filing (AI summary) 12 months ago 0 comments
  5. 5
    1

    Gyre Therapeutics Reports Q2 2025 Financial Results with $1.6M Net Income

    via official filing (AI summary) about 1 year ago 0 comments
  6. 6
    1

    Gyre Therapeutics Reports Q1 2025 Revenue Decline to $22.1 Million

    via official filing (AI summary) over 1 year ago 0 comments
  7. 7
    1

    Gyre Therapeutics Reports $17.9M Net Income for 2024, Improved Profitability Amid Revenue Decline

    via official filing (AI summary) over 1 year ago 0 comments
  8. 8
    1

    Gyre Therapeutics Reports Decline in Revenue and Operating Income in Q3 2024, Despite Strategic Progress

    via official filing (AI summary) almost 2 years ago 0 comments